Concomitant Sparsentan (SPAR) and Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients with IgA Nephropathy (IgAN) in the PROTECT Open-Label Extension (OLE)

Patient-Reported Outcomes in the PROTECT Clinical Trial Comparing Sparsentan With Irbesartan for Immunoglobulin A Nephropathy 

Sparsentan in Patients With Prior or Concurrent Immunosuppressive Treatment (IST) for IgA Nephropathy (IgAN): A Case Series 

 Sparsentan in Pediatric Patients With Rare Proteinuric Kidney Disease: Preliminary Findings From the EPPIK Study 

Health-Related Quality of Life in Adult Patients With Focal Segmental Glomerulosclerosis (FSGS): Sparsentan Versus Irbesartan 

Outcomes of the DUPLEX Trial in Patients With Genetic Focal Segmental Glomerulosclerosis (gFSGS)

Association Between Homocysteine and Clinical Outcomes in Patients With Classical Homocystinuria: A Systematic Literature Review

 The Humanistic Burden of Rare Kidney Diseases: Understanding the Impact of Immunoglobulin A Nephropathy (IgAN) and Focal Segmental Glomerulosclerosis (FSGS) on Patients and Care-Partners Study (HONUS): Results for IgAN and FSGS in Europe